SCHEMBL30294699

SCHEMBL30294699

CCOC(=O)c1cc(Cl)ccc1Nc1ccc(F)cc1OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX1 Q96LB2 7/20 0.54
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 4/20 0.47
LMNA P02545 2/20 0.47
TSHR P16473 3/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
KCNMA1 Q12791 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 2/20 0.43
TSPO P30536 1/20 0.42
HTT P42858 1/20 0.42
P2RX3 P56373 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853077 1.00 MRGPRX1 (0.54) MRGPRX1GAAL3MBTL1MAPTLMNA
SCHEMBL30294316 0.88 MRGPRX1 (0.56) MRGPRX1GAAL3MBTL1MAPTLMNA
SCHEMBL22853109 0.88 MRGPRX1 (0.56) MRGPRX1GAAL3MBTL1MAPTLMNA
SCHEMBL22853357 0.87 MAPT (0.50) MRGPRX1MAPTLMNATSHRKMT2A
SCHEMBL30294796 0.87 MAPT (0.50) MRGPRX1MAPTLMNATSHRKMT2A
SCHEMBL4364443 0.82 GAA (0.50) GAAL3MBTL1MAPTLMNATSHR
SCHEMBL22853031 0.79 KMT2A (0.51) MAPTLMNAKMT2AMEN1MAPK1
SCHEMBL30294853 0.79 KMT2A (0.51) MAPTLMNAKMT2AMEN1MAPK1
SCHEMBL22853397 0.79 MAPT (0.49) MRGPRX1MAPTLMNATSHRKMT2A
SCHEMBL30294446 0.79 LMNA (0.52) GAAL3MBTL1MAPTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B MRGPRX1 566/4885GAA 2380/4885L3MBTL1 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.